Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial

Elias Jabbour, Hagop M. Kantarjian, Yuya Sasaki et al.|The Lancet Haematology|2020

Cited by 64